CRSP | CRISPR Therapeutics AG

Why Intellia May Have Changed Medicine Forever
Genomics and gene editing is a sector that is truly in its infancy, but as we have seen this past week, that’s not stopping investors from buying up companies in the sector at high valuations.
By Mike Sakuraba | 3 weeks ago